Ultime notizie per BlackRock Technology (NYSE:BTX) Azioni

BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.

BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest

BlackRock Technology and Private Equity Term Trust

Maxim Group analyst Jason McCarthy downgrades Brooklyn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NASDAQ">BTX</a>) from Buy to Hold.

News

Downgrades

Analyst Ratings

Maxim Group Downgrades Brooklyn to Hold

Stock Split

Brooklyn ImmunoTherapeutics Announces 1-For-20 Share Consolidation

New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio 
&nbsp;
The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines
Company&#39;s shares to trade under new ticker symbol &quot;ERNA&quot; starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date

Brooklyn ImmunoTherapeutics Announces Name Change To Eterna Therapeutics And Provides Corporate Updates

<h3>Gainers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) stock rose 14.06% to $0.73. Chembio Diagnostics's trading volume hit 558.2K shares by close, accounting for 49.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $22.0 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares rose 10.51% to $3.68. The company's market cap stands at $140.0 million. </li>
<li>Lixte Biotech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares rose 8.96% to $0.83. The company's market cap stands at $13.8 million. </li>
<li>Brooklyn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NASDAQ">BTX</a>) stock moved upwards by 8.94% to $0.41. At the close, Brooklyn's trading volume reached 89.3K shares. This is 15.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $24.3 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) shares moved upwards by 8.61% to $4.79. The market value of their outstanding shares is at $36.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 9.7% to $0.32 during Thursday's after-market session. The company's market cap stands at $20.6 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock decreased by 8.26% to $2.5. The market value of their outstanding shares is at $77.7 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock declined by 7.75% to $1.43. At the close, Bright Green's trading volume reached 11.6 million shares. This is 1177.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $228.5 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 7.03% to $0.49. The market value of their outstanding shares is at $12.5 million. </li>
<li>Comera Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRA#NASDAQ">CMRA</a>) shares decreased by 6.43% to $2.04. This security traded at a volume of 1.2 million shares come close, making up 35.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $38.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock decreased by 6.26% to $2.1. The company's market cap stands at $38.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

BGXX

BTMD

CEMI

CMRA

GTBP

LIXT

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

RVPH 

SNES

VERO

12 Health Care Stocks Moving In Thursday's After-Market Session

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock moved upwards by 19.8% to $24.21 during Tuesday&#39;s after-market session. At the close, Cassava Sciences&#39;s trading volume reached 874.8K shares. This is 59.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $970.7 million.</li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares rose 10.98% to $0.78. Dermata Therapeutics&#39;s trading volume hit 1.6 million shares by close, accounting for 115.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.1 million. As per the news, the Q2 earnings report came out yesterday.</li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock increased by 10.57% to $1.15. The company&#39;s market cap stands at $13.9 million. As per the press release, Q2 earnings came out yesterday.</li>
<li>Talis Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) stock increased by 9.49% to $0.92. Today&#39;s trading volume for this security ended up closing at 88.6K shares, which is 53.4 percent of its average volume over the last 100 days. The company&#39;s market cap stands at $24.4 million.</li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 9.19% to $2.73. The market value of their outstanding shares is at $67.9 million.</li>
<li>Brooklyn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NASDAQ">BTX</a>) shares increased by 7.27% to $0.59. The market value of their outstanding shares is at $34.7 million.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eloxx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>) shares fell 14.0% to $0.35 during Tuesday&#39;s after-market session. The company&#39;s market cap stands at $30.5 million. As per the news, the Q2 earnings report came out yesterday.</li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) shares decreased by 13.64% to $1.71. PAVmed&#39;s trading volume hit 219.0K shares by close, accounting for 17.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $150.4 million. As per the news, the Q2 earnings report came out today.</li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares decreased by 8.5% to $5.82. Trading volume for this security closed at 889.9K, accounting for 1085.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.5 million.</li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock declined by 6.37% to $2.06. The company&#39;s market cap stands at $112.1 million.</li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares decreased by 5.16% to $2.21. The market value of their outstanding shares is at $30.7 million.</li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares fell 5.03% to $1.7. The company&#39;s market cap stands at $112.4 million. As per the press release, Q2 earnings came out 3 days ago. See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ARTL

BIVI

DRMA

ELOX

IMMX

INVO

MSPR

PASG

PAVM

SAVA

TLIS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

ABSI

ACHR

ACRX

AKAN

ALLG

ALVR

ANTE

AOSL

APGN

ARAY

ARHS

ARVL

ASTR

ASTS

ATNX

BFLY

BGRY

BMBL

BRCC

BRFS

BROS

CASI

CDXC

CERE

COIN

CYCC

CYXT

DPSI

DRCT

DWSN

ENSC

ENVX

EQRX

FAZE

FEAM

FPAY

GETY

GMBL

GMDA

HUMA

HYPR

IVDA

MDWT

MTTR

NOAH

NOTV

NVTA

NYMX

OCUP

PAAS

PAGS

PIXY

PXLW

QTRX

RANI

RCMT

RRGB

SEER

SGHC

SNCE

SOND

SONO

STAA

STKL

STRY

TANH

TKNO

TMBR

TSHA

TTOO

VCSA

VERU

VJET

VZIO

WETG

WRBY

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday

<h3>Gainers</h3>
<ul>
<li>Timber Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmbr#NYSE">TMBR</a>) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.</li>
<li>T2 Biosystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttoo#NASDAQ">TTOO</a>) shares jumped 50.6% to $0.2379. T2 Biosystems shares jumped over 30% on Wednesday after the company on Tuesday announced it will explore the potential to develop a rapid molecular diagnostic test for monkeypox.</li>
<li>FlexShopper, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fpay#NASDAQ">FPAY</a>) rose 38.6% to $1.5519 after reporting Q2 results.</li>
<li>Esports Entertainment Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmbl#NASDAQ">GMBL</a>) shares jumped 33.6% to $0.6078 after Massachusetts Governor Baker on Wednesday signed a sports betting bill into law.</li>
<li>AcelRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrx#NASDAQ">ACRX</a>) surged 30.8% to $0.3075. The company on Wednesday announced acceptance for a podium presentation at the ANESTHESIOLOGY 2022 Annual Meeting.</li>
<li>Veru Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) shares gained 30.5% to $15.36 after the company reported Q3 earnings results.</li>
<li>SmileDirectClub, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdc#NASDAQ">SDC</a>) jumped 29% to $1.68 as the stock reversed from weakness earlier in the week. The stock fell Monday after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.</li>
<li>Enovix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envx#NASDAQ">ENVX</a>) rose 28.6% to $20.81 following Q2 results.</li>
<li>CASI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casi#NASDAQ">CASI</a>) gained 27.9% to $3.85. CASI Pharmaceuticals is set to host a conference call reviewing the Q2 financial results on Friday, August 12th, 2022.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) jumped 27.5% to $11.68. AST SpaceMobile recently announced that its test satellite has arrived at the launch location for its upcoming planned launch.</li>
<li>Nymox Pharmaceutical Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nymx#NASDAQ">NYMX</a>) gained 27% to $0.5713.</li>
<li>Vacasa, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcsa#NASDAQ">VCSA</a>) shares rose 26.4% to $3.8410 after posting upbeat quarterly sales.</li>
<li>Inotiv, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/notv#NASDAQ">NOTV</a>) jumped 25.8% to $26.08 after the company reported better-than-expected Q3 sales results.</li>
<li>Absci Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/absi#NASDAQ">ABSI</a>) gained 25.7% to $5.28 after the company posted a narrower Q2 loss.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) climbed 24.9% to $6.48 after the company reported better-than-expected Q2 EPS results and issued Q3 and FY22 EPS and sales guidance above estimates.</li>
<li>Digital Media Solutions, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dms#NYSE">DMS</a>) gained 24.5% to $1.4699. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results</li>
<li>Wave Life Sciences Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wve#NASDAQ">WVE</a>) jumped 24.2% to $3.1687 after the company reported Q2 EPS results were up year over year.</li>
<li>Sonder Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sond#NASDAQ">SOND</a>) gained 24% to $2.6450 after the company reported better-than-expected Q2 sales results.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) gained 23.7% to $1.7450 after board member Michael Lehman reported a large insider buy on August 10 in a Form4 filing.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drct#NASDAQ">DRCT</a>) shares gained 22% to $3.1121 after the company reported better-than-expected Q2 EPS results.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) gained 22.2% to $10.91. SunOpta raised its FY22 revenue guidance.</li>
<li>Arhaus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arhs#NASDAQ">ARHS</a>) jumped 21.8% to $7.80 after the company reported better-than-expected Q2 adjusted EPS and sales results and raised FY22 sales guidance above estimates.</li>
<li>Quanterix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtrx#NASDAQ">QTRX</a>) jumped 19.6% to $10.24. Quanterix Director Paul Meister reported the purchase of 234,304 shares at an average price of $8.53 per share in Form 4 filing.</li>
<li>Warby Parker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wrby#NYSE">WRBY</a>) gained 19.5% to $16.94 after the company reported Q2 EPS results were higher year over year and better-than-expected Q2 sales results.</li>
<li>Accuray Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aray#NASDAQ">ARAY</a>) rose 18.4% to $2.58 after the company reported better-than-expected Q4 EPS and sales results.</li>
<li>TOP Financial Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/top#NASDAQ">TOP</a>) gained 18.4% to $14.96.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) jumped 18.3% to $3.7050 after Synlogic announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>) jumped 18.1% to $9.08.</li>
<li>Butterfly Network, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NYSE">BFLY</a>) gained 17.6% to $7.87.</li>
<li>Rite Aid Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rad#NYSE">RAD</a>) gained 17.4% to $11.08.</li>
<li>VIZIO Holding Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vzio#NYSE">VZIO</a>) jumped 17.2% to $12.24 after the company reported Q2 EPS results were higher year over year and issued Q3 guidance.</li>
<li>Zymergen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zy#NASDAQ">ZY</a>) gained 16.8% to $3.2727. JP Morgan upgraded Zymergen from Underweight to Neutral.</li>
<li>Brooklyn ImmunoTherapeutics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/btx#NYSE">BTX</a>) jumped 15.6% to $0.60.</li>
<li>BRC Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) gained 14.8% to $9.90 following Q2 results.</li>
<li>Applied Industrial Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ait#NYSE">AIT</a>) gained 13.6% to $120.54 after the company reported better-than-expected Q4 EPS and sales results and issued FY23 EPS guidance above analyst estimates. Also, the company announced a 1.5 million share buyback.</li>
<li>Noah Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noah#NYSE">NOAH</a>) gained 13.3% to $18.88.</li>
<li>Archer Aviation Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/achr#NYSE">ACHR</a>) rose 13.2% to $4.79. Archer Aviation said it received $10 million pre-delivery payment from United Airlines for 100 eVTOL Aircraft.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) shares gained 12% to $1.49 after the company posted a narrower Q2 loss.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aosl#NASDAQ">AOSL</a>) jumped 11.3% to $42.11 after the company reported better-than-expected Q4 EPS and sales results.</li>
<li>Tantech Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tanh#NASDAQ">TANH</a>) rose 9.7% to $0.3111.</li>
<li>Aegon N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aeg#NYSE">AEG</a>) rose 8.8% to $5.05 after the company increased its projections for operating capital generation and free cashflow.</li>
<li>Dutch Bros Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bros#NYSE">BROS</a>) gained 8.3% to $47.67 after the company reported better-than-expected Q2 sales results.</li>
<li>The Walt Disney Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>) rose 6.1% to $119.27 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Coupang, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cpng#NYSE">CPNG</a>) rose 3.3% to $20.42 after the company reported second-quarter revenue growth of 12.5% year-over-year to $5.04 billion, +27% on a constant currency basis.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Athenex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnx#NASDAQ">ATNX</a>) shares dipped 49.4% to $0.5613 after the company reported pricing of $30 million public offering of common stock and warrants.</li>
<li>Invitae Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvta#NYSE">NVTA</a>) shares tumbled 43.5% to $4.88. Invitae shares surged around 277% on Wednesday after the company reported better-than-expected Q2 EPS.</li>
<li>Sonos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sono#NASDAQ">SONO</a>) shares fell 25% to $17.07 after the company reported weaker-than-expected sales results for its third quarter and issued downbeat FY22 sales guidance. The company also announced that its CFO Brittany Bagley is stepping down to pursue another professional opportunity. Eddie Lazarus, the company&#39;s chief legal officer, will succeed Bagley as interim CFO, effective Sept. 1.</li>
<li>AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) dipped 24.8% to $6.47. AlloVir recently posted a Q2 loss of $0.69 per share.</li>
<li>Seer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seer#NASDAQ">SEER</a>) dropped 24.4% to $10.06 after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $20 to $12.</li>
<li>Marqeta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mq#NASDAQ">MQ</a>) fell 23.3% to $8.48 after the company reported financial results for the second quarter.</li>
<li>Hyperfine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hypr#NASDAQ">HYPR</a>) fell 22.6% to $1.4399 after the company posted downbeat Q2 results and issued weak FY22 revenue forecast.</li>
<li>Outbrain Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ob#NASDAQ">OB</a>) dipped 22.3% to $5.22 after the company reported worse-than-expected Q2 EPS results.</li>
<li>Six Flags Entertainment Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/six#NYSE">SIX</a>) fell 21.2% to $20.33 after the company said Q2 EPS results were down year over year and reported worse-than-expected Q2 sales results.</li>
<li>Arrival (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvl#NASDAQ">ARVL</a>) dropped 20.6% to $1.4750 after the company announced the establishment of a $300 million At The Market platform. The company also said it expects lower production volumes in 2022 compared to prior estimates.</li>
<li>RCM Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcmt#NASDAQ">RCMT</a>) declined 20% to $15.16 after the company reported worse-than-expected Q2 sales.</li>
<li>Berkshire Grey, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgry#NASDAQ">BGRY</a>) fell 19.9% to $2.2101 after reporting a Q2 loss.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) dipped 19.8% to $8.90 after the company announced a proposed public offering of class A common stock.</li>
<li>EQRx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eqrx#NASDAQ">EQRX</a>) fell 18.8% to $4.8650 after the company reported Q2 earnings results.</li>
<li>Pixelworks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxlw#NASDAQ">PXLW</a>) declined 18% to $2.04 after reporting a wider quarterly loss.</li>
<li>Starry Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stry#NYSE">STRY</a>) fell 17% to $3.16.</li>
<li>ChromaDex Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxc#NASDAQ">CDXC</a>) dropped 17% to $1.7089 after the company reported worse-than-expected Q2 EPS and sales results.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) fell 15.5% to $13.59.</li>
<li>Red Robin Gourmet Burgers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rrgb#NASDAQ">RRGB</a>) fell 15% to $9.05 after the company reported Q2 adjusted EPS results were down year over year and worse-than-expected Q2 sales results. Additionally, Benchmark downgraded the stock from Buy to Hold.</li>
<li>Pan American Silver Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/paas#NASDAQ">PAAS</a>) shares fell 14.4% to $18.03 after the company reported Q2 results.</li>
<li>Unifi, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ufi#NYSE">UFI</a>) fell 12.6% to $12.77 following Q4 results.</li>
<li>AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) fell 11.6% to $35.71 after the company reported Q2 EPS results were down year over year and worse-than-expected Q2 sales results and lowered FY22 sales guidance below estimates.</li>
<li>Super Group (SGHC) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sghc#NYSE">SGHC</a>) fell 10.7% to $5.05 after reporting Q2 results.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) fell 10.3% to $1.0580 after declining around 6% on Wednesday.</li>
<li>Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) fell 9.7% to $2.89 after gaining 7% on Wednesday.</li>
<li>Broadstone Net Lease, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bnl#NYSE">BNL</a>) fell 6.6% to $20.91 as the company priced 13 million share public offering of common stock at $21.35 per share.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensc#NASDAQ">ENSC</a>) fell 6.6% to $0.4990. Ensysce Biosciences reported completion of $8 million convertible note financing.</li>
<li>Bumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmbl#NASDAQ">BMBL</a>) fell 6.5% to $32.25 after the company reported worse-than-expected Q2 EPS results and issued Q3 and FY22 sales guidance below estimates.</li>
<li>Iveda Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivda#NASDAQ">IVDA</a>) fell 5.8% to $1.28. Iveda Solutions recently reported a $5 million private placement.</li>
</ul>

Intraday Update

CPNG

PACB

Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session

&nbsp;
Wednesday saw 83 companies set new 52-week lows.
<h2>Areas of Interest About Today&#39;s 52-Week Lows:</h2>
<ul>
<li>Orange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORAN#NYSE">ORAN</a>) was the largest firm on a market cap basis to set a new 52-week low.</li>
<li>The smallest company by market cap to set a new 52-week low was Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>).</li>
<li>F45 Training Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXLV#NYSE">FXLV</a>)&#39;s stock came under the most pressure, trading down 74.98% to reach a new 52-week low.</li>
<li>LL Flooring Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>)&#39;s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low.</li>
</ul>
The stocks that set new 52-week lows on Wednesday:
<ul>
<li>Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares moved up 0.1% on Wednesday to hit a new 52-week low of $9.61, drifting up 0.1%.</li>
<li>Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) stock hit $26.20 on Wednesday morning, setting a new 52-week low for a change of down 1.75%.</li>
<li>RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) stock achieved a new 52-week low on Wednesday morning, hitting $132.91 and moving down 1.2%.</li>
<li>Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) stock set a new 52-week low of $36.67 on Wednesday, moving down 16.54%.</li>
<li>Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) shares made a new 52-week low of $12.88 on Wednesday. The stock was down 1.19% for the day.</li>
<li>Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) stock dropped to a yearly low on Wednesday of $26.08. Shares traded up 0.46%.</li>
<li>Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) shares made a new 52-week low of $31.06 on Wednesday. The stock was down 2.78% for the day.</li>
<li>Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) shares were up 4.46% for the day, having made a 52-week low of $33.13.</li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock drifted up 2.17% on Wednesday morning to hit a new 52-week low of $3.15.</li>
<li>Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) shares moved down 6.01% on Wednesday to hit a new 52-week low of $7.70, drifting down 6.01%.</li>
<li>Pros Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRO#NYSE">PRO</a>) shares hit a yearly low of $23.01. The stock was up 1.32% on the session.</li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock broke to a new 52-week low of $13.84 on Wednesday. Shares of the company traded down 19.75%.</li>
<li>Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) stock set a new 52-week low of $4.56 on Wednesday, moving down 0.41%.</li>
<li>New Found Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NFGC#AMEX">NFGC</a>) shares fell to $3.62 on Wednesday, setting a new 52-week low with a shift of up 0.52%.</li>
<li>Insteel Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) stock achieved a new 52-week low on Wednesday morning, hitting $29.89 and moving up 2.31%.</li>
<li>Big Lots (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) shares reached a new 52-week low of $18.16 on Wednesday morning, moving down 0.3%.</li>
<li>Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) shares were down 3.12% for the day, having made a 52-week low of $20.20.</li>
<li>Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) shares hit a yearly low of $3.71. The stock was up 0.78% on the session.</li>
<li>SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) shares set a new yearly low of $1.70 this morning. The stock was up 1.74% on the session.</li>
<li>LL Flooring Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) stock hit $9.11 on Wednesday morning, setting a new 52-week low for a change of 0.0% (flat).</li>
<li>Whole Earth Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FREE#NASDAQ">FREE</a>) stock hit a yearly low of $5.51. The stock was up 0.18% for the day.</li>
<li>a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) shares made a new 52-week low of $1.80 on Wednesday. The stock was down 5.2% for the day.</li>
<li>Doma Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOMA#NYSE">DOMA</a>) shares set a new 52-week low of $0.69. The stock traded up 1.17%.</li>
<li>Vinco Ventures (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) stock drifted up 5.9% on Wednesday morning to hit a new 52-week low of $0.76.</li>
<li>Embark Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBK#NASDAQ">EMBK</a>) stock hit a yearly low of $0.35. The stock was up 0.97% for the day.</li>
<li>Party City Holdco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRTY#NYSE">PRTY</a>) shares fell to $1.05 on Wednesday, setting a new 52-week low with a shift of down 0.92%.</li>
<li>Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) shares reached a new 52-week low of $1.64 on Wednesday morning, moving up 0.3%.</li>
<li>Genetron Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTH#NASDAQ">GTH</a>) shares hit a yearly low of $1.13. The stock was down 1.74% on the session.</li>
<li>EVI Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EVI#AMEX">EVI</a>) shares reached a new 52-week low of $7.25 on Wednesday morning, moving up 1.71%.</li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock set a new 52-week low of $3.90 on Wednesday, moving down 1.26%.</li>
<li>Lytus Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) shares made a new 52-week low of $2.30 on Wednesday. The stock was down 2.46% for the day.</li>
<li>Applied Molecular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTI#NASDAQ">AMTI</a>) shares reached a new 52-week low of $1.91 on Wednesday morning, moving up 2.56%.</li>
<li>Cortexyme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTX#NASDAQ">CRTX</a>) stock achieved a new 52-week low on Wednesday morning, hitting $1.80 and moving up 1.63%.</li>
<li>Heritage Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) stock broke to a new 52-week low of $2.26 on Wednesday. Shares of the company traded down 1.3%.</li>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) stock hit a yearly low of $1.45. The stock was down 1.33% for the day.</li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares hit a yearly low of $3.68. The stock was down 1.74% on the session.</li>
<li>Conformis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFMS#NASDAQ">CFMS</a>) shares set a new 52-week low of $0.26. The stock traded up 1.95%.</li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares were down 3.02% for the day, having made a 52-week low of $2.54.</li>
<li>Oriental Culture Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCG#NASDAQ">OCG</a>) shares made a new 52-week low of $2.25 on Wednesday. The stock was 0.0% (flat) for the day.</li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) shares moved down 3.55% on Wednesday to hit a new 52-week low of $0.76, drifting down 3.55%.</li>
<li>Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) stock set a new 52-week low of $0.60 on Wednesday, moving up 0.03%.</li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares set a new 52-week low of $0.55. The stock traded down 1.55%.</li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares were down 1.25% for the day, having made a 52-week low of $1.84.</li>
<li>Clever Leaves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLVR#NASDAQ">CLVR</a>) stock hit a new 52-week low of $0.90. The stock was up 0.68% on the session.</li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) shares were up 4.1% for the day, having made a 52-week low of $0.85.</li>
<li>ObsEva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBSV#NASDAQ">OBSV</a>) shares set a new 52-week low of $0.42. The stock traded down 72.86%.</li>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) stock hit a new 52-week low of $1.36. The stock was down 1.89% on the session.</li>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) shares set a new 52-week low of $0.70. The stock traded down 1.94%.</li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock broke to a new 52-week low of $1.73 on Wednesday. Shares of the company traded down 1.64%.</li>
<li>Eargo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAR#NASDAQ">EAR</a>) shares hit a yearly low of $0.70. The stock was down 1.03% on the session.</li>
<li>Brooklyn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NASDAQ">BTX</a>) shares were down 3.64% for the day, having made a 52-week low of $0.45.</li>
<li>Humanigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGEN#NASDAQ">HGEN</a>) shares made a new 52-week low of $0.38 on Wednesday. The stock was down 9.22% for the day.</li>
<li>Talis Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares fell to $0.79 on Wednesday, setting a new 52-week low with a shift of down 1.25%.</li>
<li>Integrated Media Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTE#NASDAQ">IMTE</a>) shares made a new 52-week low of $1.31 on Wednesday. The stock was down 10.85% for the day.</li>
<li>MediaCo Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) shares were 0.0% (flat) for the day, having made a 52-week low of $1.49.</li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock set a new 52-week low of $0.41 on Wednesday, moving down 0.38%.</li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock broke to a new 52-week low of $0.55 on Wednesday. Shares of the company traded down 8.82%.</li>
<li>Jupiter Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUPW#NASDAQ">JUPW</a>) shares hit a yearly low of $0.59. The stock was up 3.03% on the session.</li>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) shares made a new 52-week low of $1.47 on Wednesday. The stock was up 1.27% for the day.</li>
<li>Greenpro Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNQ#NASDAQ">GRNQ</a>) stock hit a new 52-week low of $0.15. The stock was down 8.85% on the session.</li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares hit a yearly low of $0.35. The stock was down 0.3% on the session.</li>
<li>Cuentas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUEN#NASDAQ">CUEN</a>) stock broke to a new 52-week low of $0.49 on Wednesday. Shares of the company traded down 2.2%.</li>
<li>ECMOHO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOHO#NASDAQ">MOHO</a>) shares moved down 3.09% on Wednesday to hit a new 52-week low of $0.12, drifting down 3.09%.</li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock set a new 52-week low of $0.95 on Wednesday, moving down 14.16%.</li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares set a new yearly low of $0.46 this morning. The stock was down 4.36% on the session.</li>
</ul>
Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. <a href="https://pro.benzinga.com/?afmc=2a&amp;utm_source=benzinga.com&amp;utm_medium=web&amp;utm_campaign=premium_products">Click here to learn more</a>.

Options

AGFY

ALRS

AMTI

AUGX

AUPH

BBIG

CFMS

CLVR

CRTX

CUEN

CURV

DOMA

EFTR

EMBK

EXPR

FLGC

FREE

FXLV

GRNQ

HEPA

HGEN

HRTG

HSDT

IIIN

ILAG

IMTE

JNPR

JUPW

LTRY

MDIA

MOHO

NEGG

NFGC

NRGV

OBSV

OKYO

ORAN

PRTY

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RSLS

SHOO

SIEN

SLNH

SLQT

SNAP

TENB

VRME

WINT

WOOF

Stocks That Hit 52-Week Lows On Wednesday

<ul>
<li>European Commission (EC) has approved AbbVie&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume of 4.85 million shares, closed regular trading session at $150.87.</li>
</ul>
<ul>
<li>Medicines and Healthcare products Regulatory Agency (MHRA) has granted UK marketing authorization for Global Blood Therapeutics&rsquo; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbt#NASDAQ">GBT</a>) Oxbryta&nbsp;(voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older. Global Blood Therapeutics shares traded in a range of $32.43 to $34.03 on a day volume of 808.38 thousand shares, closed regular trading session at $33.35.</li>
</ul>
<ul>
<li>Seagen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgen#NASDAQ">SGEN</a>) and Astellas Pharma announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV&reg;&nbsp;(enfortumab vedotin-ejfv) in combination with Merck&#39;s anti-PD-1 therapy KEYTRUDA&reg;&nbsp;(pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer. Seagen shares traded in a range of $174.14 to $181.67 on a day volume of 1.64 million shares, closed regular trading session at $177.51.</li>
</ul>
<ul>
<li>MediciNova (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) announced the initiation of a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and hypertriglyceridemia. MediciNova shares traded in a range of $2.39 to $2.5 on a day volume of 14.14 thousand shares, closed regular trading session at $2.39.</li>
</ul>
<ul>
<li>Clearside Biomedical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsd#NASDAQ">CLSD</a>) completed dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD). Clearside shares traded in a range of $1.55 to $1.67 on a day volume of 84.52 thousand shares, closed regular trading session at $1.62.</li>
</ul>
<ul>
<li>The U.S. Food and Drug Administration (FDA) has accepted Biogen&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The regulatory agency as granted priority review and assigned PDUFA&nbsp; action date of January 25, 2023. Biogen shares traded in a range of $206.7 to $214 on a day volume of 909.79 thousand shares, closed regular trading session at $210.85.</li>
</ul>
<ul>
<li>Reneo Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rphm#NASDAQ">RPHM</a>) positive results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development updates. Reneo shares traded in a range of $2.99 to $3.66 on a day volume of 401.39 thousand shares, closed regular trading session at $3.3. The company shares are currently trading at $3.21, down 2.73 percent in the after-hours trading session.</li>
</ul>
<ul>
<li>Brooklyn (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btx#NASDAQ">BTX</a>) reported results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. Brooklyn shares traded in a range of $0.49 to $0.53 on a day volume of 451.46 thousand shares, closed regular trading session at $0.49.</li>
</ul>
<ul>
<li>MyMD (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mymd#NASDAQ">MYMD</a>) announced further advancement of its fully funded Phase 2 clinical trial of lead drug candidate MYMD-1&nbsp;as a therapy for delaying aging and expanding healthy lifespan. To date, the trial has completed dosing for the first patient cohort and dosing has been initiated in the next higher dose cohort. MyMD shares traded in a range of $3.48 to $4 on a day volume of 237.33 thousand shares, closed regular trading session at $3.49.</li>
</ul>
<ul>
<li>BridgeBio Pharma (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbio#NASDAQ">BBIO</a>) announced positive interim results from PROPEL 2, a Phase 2 trial of the investigational therapy Infigratinib in children with Achondroplasia (ACH). BridgeBio shares traded in a range of $9.22 to $11.95 on a day volume of 5.95 million shares, closed regular trading session at $9.29.</li>
</ul>
<ul>
<li>Oramed Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ormp#NASDAQ">ORMP</a>) has enrolled over&nbsp;50 percent&nbsp;of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D). Oramed shares traded in a range of $7.63 to $8.12 on a day volume of 381.33 thousand shares, closed regular trading session at $7.82. The company shares are currently trading at $8.11, up 3.71 percent in the after-hours trading session.</li>
</ul>
<ul>
<li>CinCor Pharma (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cinc#NASDAQ">CINC</a>) has concluded patient enrolment in Phase 2 HALO trial of Baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension. CinCor shares traded in a range of $21.11 to $24.64 on a day volume of 132.14 thousand shares, closed regular trading session at $23. The company shares are currently trading at $22.45, down 2.39 percent in the after-hours trading session.</li>
</ul>
<ul>
<li>The U.S. Food and Drug Administration (FDA) provided favorable feedback on the Current Good Manufacturing Practice (cGMP) design of Applied Genetic Technologies&rsquo; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agtc#NASDAQ">AGTC</a>) manufacturing facility. In its feedback from a recent Type C meeting, the FDA concurred the facility design and proposed operating procedures are appropriate to support the cGMP manufacture of recombinant AAV drug substance. Applied Genetic shares traded in a range of $0.37 to $0.38 on a day volume of 1.76 milion shares, closed regular trading session at $0.38.</li>
</ul>
<ul>
<li>The Japan Ministry of Health, Labour and Welfare (MHLW) granted expanded manufacturing and marketing approval from for Novavax&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine towards primary immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17 years. Novavax shares traded in a range of $54.14 to $58.73 on a day volume of 4.77 million shares, closed regular trading session at $56.55.</li>
</ul>
<ul>
<li>Synaptogenix (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase&nbsp;2b&nbsp;clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer&#39;s disease (AD). Synaptogenix shares traded in a range of $5.18 to $5.6 on a day volume of 144.75 thousand shares, closed regular trading session at $5.42.</li>
</ul>

Biotech

Health Care

General

ABBV

AGTC

BBIO

BIIB

CINC

CLSD

MNOV

NVAX

ORMP

RPHM

SGEN

SNPX

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

<ul>
<li>Brooklyn ImmunoTherapeutics Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btx#NASDAQ">BTX</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/07/g28201567/brooklyn-immunotherapeutics-announces-results-of-phase-2-study-of-irx-2-in-head-and-neck-cancer" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">announced results</a>&nbsp;from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.</li>
<li>The study&#39;s primary endpoint was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2.&nbsp;</li>
<li>150 patients were enrolled in the study. At two years of follow-up in the intention-to-treat (n=105) population, the median EFS was 48.3 months and was not reached in the control arm (Hazard Ratio 1.10).</li>
<li>In key pre-specified subgroups, outcomes favored IRX-2.&nbsp;</li>
<li>Patients in these subgroups were less likely to experience an EFS event in the IRX-2 arm compared to the control.&nbsp;</li>
<li>Trends in EFS rates at two years of follow-up in patients with the later-stage disease were 57.2 vs. 49.4 in favor of IRX-2.&nbsp;</li>
<li>In patients that did not receive chemotherapy (radiation only) as part of adjuvant treatment, the EFS was 76.4 vs. 60.6 in favor of IRX-2.&nbsp;</li>
<li>There were no new safety signals observed with IRX-2. Adverse events related to study treatment were injection site reactions and fatigue.</li>
<li>Price Action:&nbsp;BTX shares are down 4.75% at $0.50 on the last check Tuesday.</li>
</ul>

Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study

<a href="https://www.globenewswire.com/Tracker?data=03AGrks8FjUdbGhtB_jJg_UxREoXJDnmdqPZX-fXTOSbciuJRBnxE4bEz16KxVq9Xah_d8EZbsI61RfkuSvcEEd55eK7SP_y-2NuTdDvwTQ=" target="_blank">Brooklyn ImmunoTherapeutics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NASDAQ">BTX</a>) (&ldquo;Brooklyn&rdquo; or the &ldquo;Company&rdquo;) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.
The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat (ITT, n=105) population the median EFS was 48.3 months and was not reached in the control arm (Hazard Ratio 1.10 (95% Confidence Interval, 0.6-2.1; p value=0.62)).
In key pre-specified subgroups defined by stage and type of adjuvant treatment, outcomes favored IRX-2. Patients in these subgroups were less likely to experience an EFS event in the IRX-2 arm compared to control. Trends in EFS rates as defined by the Kaplan-Meier estimate at two years of follow-up in patients with later stage (III and IV) disease were 57.2 (40.3, 70.9) vs 49.4 (28.3, 67.4) in favor of IRX-2. In patients that did not receive chemotherapy (radiation only) as part of adjuvant treatment, the EFS Kaplan-Meier estimate at two years of follow-up was 76.4 (52.2, 89.4) vs 60.6 (29.4, 81.4) in favor of IRX-2. There were no new safety signals observed with IRX-2. Adverse events related to study treatment were higher in the IRX-2 arm than the control arm (55.9% vs 40%) and were driven primarily by injection site reactions and fatigue.
&ldquo;We thank the patients and their families for their participation in this trial,&rdquo; said Roger Sidhu, M.D., Brooklyn&rsquo;s Chief Medical Officer. &ldquo;IRX-2 immunotherapy treatment was administered as a local subcutaneous injection and was well tolerated in this patient population with squamous cell head and neck cancer of the oral cavity in the neoadjuvant setting. We observed compelling trends in favor of IRX-2 in patients with higher stage disease and those that did not receive chemotherapy as part of adjuvant treatment, representing patient populations with high unmet need and who comprise a significant proportion of patients with head and neck cancer. The mechanism of action of IRX-2 and prior preclinical and translational studies of IRX-2 suggest potential synergy with checkpoint inhibitors and represents a novel combination immunotherapy strategy to explore in patients that may not be eligible for or require intensive adjuvant treatment.&rdquo;
&ldquo;The INSPIRE study achieved its primary objective of identifying patient populations that may benefit from IRX-2 in the neoadjuvant setting,&rdquo; said Matt Angel, Ph.D., Brooklyn&rsquo;s CEO. &ldquo;These encouraging results are a testament to the design of the INSPIRE study and provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors. The potential to offer an effective, well tolerated treatment to patients with advanced head and neck cancer who are ineligible for chemotherapy is particularly exciting.&rdquo;
The Company plans to present the results of the INSPIRE study at a scientific conference later this year.

Brooklyn ImmunoTherapeutics Announces Results Of Phase 2 Study Of IRX-2 In Head And Neck Cancer

Comments

BlackRock Technology

Notizie

Ultime notizie per BlackRock Technology (NYSE:BTX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO